Nektar Therapeutics
NKTR
288 hedge funds and large institutions have $3.24B invested in Nektar Therapeutics in 2019 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 126 increasing their positions, 86 reducing their positions, and 82 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 86
0.42% more ownership
Funds ownership: 6.36% → 6.77% (+0.42%)
0% less call options, than puts
Call options by funds: $34M | Put options by funds: $34.1M
14% less funds holding
Funds holding: 336 → 288 (-48)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less capital invested
Capital invested by funds: $5.91B → $3.24B (-$2.66B)
59% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$276M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$86.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$52M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$37.8M |
| 5 |
Millennium Management
New York
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$135M |
| 2 |
BM
Bridger Management
New York
|
-$38.6M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$26M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$25.4M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$24.2M |
NKTR Hedge Fund Activity: Q3 2019 in Review
288 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2019, worth a combined $3.24B — down 45% from $5.91B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of NKTR and 34 opened new positions — a net loss of 48 holders — while 86 trimmed existing stakes and 126 added.
The largest buyer was Invesco, adding an estimated $276M. The largest seller was Fidelity Investments, cutting an estimated $135M.
- 288 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2019, down from 336 in Q2 2019.
- Funds reported $3.24B of Nektar Therapeutics stock for Q3 2019, down 45% quarter-over-quarter.
- 34 funds opened new Nektar Therapeutics positions in Q3 2019 and 82 closed out, a net change of -48 holders.
- The largest Nektar Therapeutics buyer in Q3 2019 was Invesco, an estimated $276M added.
- The largest Nektar Therapeutics seller in Q3 2019 was Fidelity Investments, an estimated $135M sold.
Based on aggregated 13F filings for Q3 2019.